<DOC>
	<DOCNO>NCT02778776</DOCNO>
	<brief_summary>Type 2 diabetes mellitus , insulin resistance , visceral obesity disorder lipid metabolism , especially triglyceride hypertension metabolic disorder play central role pathophysiology metabolic syndrome , ultimately , cardiovascular morbidity mortality associate atherosclerosis , myocardial infarction , cerebral vascular event , vascular dementia , heart failure end stage renal disease . Recently complication related hyperinsulinemia like prostate benign hypertrophy ( BPH ) . Metformin treatment choice patient metabolic syndrome , give low cost comparable pharmacological effect tiazolinedionas ( eg pioglitazone ) , decrease hyperinsulinemia , insulin resistance , concentration free fatty acid triglyceride , also produce moderate weight loss , improve metabolic profile triglcerides atherogenic lipid carbohydrate delaying onset diabetes mellitus individual impair fast glucose . A second option risk reduction would addition inulin fiber type demonstrate metabolic effect benefice lipid metabolism carbohydrate . It expect combination metformin inulin produce beneficial effect farmacological synergism impact fisiopatological change metabolic syndrome potentially consider important risk factor prostate growth .</brief_summary>
	<brief_title>Combination Metformine/Inulin Versus Metformin Prostate Benign Hyperplasia Metabolic Syndrome</brief_title>
	<detailed_description>The main objective evaluate effect combination metformin / inulin clinical , urodynamic parameter well metabolic inflammatory profile patient benign prostate hypertrophy metabolic syndrome . The investigator conduct double-blind trial , randomize , 4 group , group 15 male female patient 40 80 year age METS diagnose IDF criterion clinical diagnose HBP . Randomization determine receive intervention 12 week trial , group like : Group ( A ) intervention combination metformin/ inulin : 15 individual recieved combination metformin/ agave inulin dosis 500 mg / 10 grs per 24hrs 12 week . Group ( B ) Metformin plus Placebo agave inulin : 15 individual recieved Metformin dosis 500mg per day ( first bite second meal ) plus homologue placebo agave inulin ( calcinated magnesia ) dosis 10grs 24 hr 12 week . Group ( C ) agave inulin plus placebo Metformin : 15 indivuduals recieved agave inulin dosis 10grs per 24hrs plus homologate placebo metformin ( calcinated magnesia ) dosis 500 mg per day ( first bite second meal ) 12 week . Group ( D ) Placebo agave inulin plus Placebo Metformin : homologate placebo agave inulin ( calcinated magnesia ) dosis 10 grs 24 hr plus homologate placebo metformin ( calcinated magnesia capsule ) dosis 500 mg per day ( first bite second meal ) 12 week . The clinical finding laboratory test include metabolic profile biosafety , baseline 12 week . Clinical component Mets like antropometrics parameter , fast glucose , fast insulin , blood lipid , clinical finding HBP inflammation parameter adipocitocins , IGF-1 , insulin , prostatic specific antigen . Adverse event adherence treatment document . Statistical analysis : Mann-Whitney U Test Wilcoxon exact test . It consider significance p &lt; 0.05 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>Diagnosis metabolic syndrome IDF criterion person define metabolic syndrome must : Central obesity ( defined waist circumference* ethnicity specific value ) ≥80 cm female ≥90 cm male ; plus two follow four factor : Raised triglyceride ≥ 150 mg/dL ( 1.7 mmol/L ) specific treatment lipid abnormality Reduced HDL cholesterol &lt; 40 mg/dL ( 1.03 mmol/L ) males &lt; 50 mg/dL ( 1.29 mmol/L ) females specific treatment lipid abnormality Raised blood pressure systolic BP ≥ 130 diastolic BP ≥ 85 mm Hg treatment previously diagnose hypertension Raised fast plasma glucose ( FPG ) ≥ 100 mg/dL ( 5.6 mmol/L ) , previously diagnose type 2 diabetes Age range 40 80 year old Male patient Informed write consent Kidney disease Hepatic disease Thyroid disease Diabetes mellitus Ischemic heart disease Drug consumption Alcohol consumption 2 ounce daily Consumption drug intervene lipid glucose metabolism 2 month Blood pressure &gt; 160/100mmHg . Lack adherence treatment ( adherence &lt; 80 % )</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Agave Inulin</keyword>
	<keyword>METS</keyword>
	<keyword>Inflammation parameter</keyword>
	<keyword>Urodynamic parameter</keyword>
	<keyword>Prostate hyperplasia</keyword>
</DOC>